Biomedical subjects

M R Freitas

Publications and source records attributed to M R Freitas.

3 recordsLinked to original sources

PubMed1978

[Thrombosis of the anterior and middle cerebral arteries as the 1st manifestation of systemic lupus erythematosus: report of a case].

The case of a young female patient with hemiplegia and aphasia of sudden onset as the initial manifestation of systemic lupus erythematosus is reported. The arteriographic study showed occlusion of the proximal portion of the left anterior cerebral artery and of the trifurcation of the left middle cerebral artery. The neurological manifestations in systemic lupus erythematosus may appear before there is any clinical evidence of involvement of others organs. The authors think that systemic lupus erythematosus should be suspected in every young female patient with acute cerebrovascular accident of unknown etiology.

Adolescent↗

PubMed1977

[Neuropathology of Chagas' disease].

CNS involvement includes: 1) acute phase: scattered focal meningoencephalitic lesions, meningeal and cerebral edema, disseminated microgranulomas containing microgliocytes and situated in relation to cerebral blood vessels, and moderate cerebral fluid pleocytosis. Acute chagasic meningoencephalitis is always fatal, and does not become chronic, as occurres with the myocardial lesions; 2) chronic phase: tromboembolic phenomena due to the chronic myocarditis, and cerebral and cerebelar atrophy of obscure pathogenesis and without inflammatory changes. B) vegetative nervous system involvement includes: 1) acute phase: neuronal destruction, with neuronal loss of varying intensity; 2) chronic phase: visceral dilatation due to neuronal loss during the acute phase.

Autonomic Nervous System↗

PubMed1976

The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.

The AA. study 60 cases of Parkinsonism treated with levodopa associated to G31,406 (dibenzazepnic derivative), to amantadine and to a placebo. Drug-associations: 1) L-dopa + G 31.406, of anticataleptic effect, probably because of its anticholinergic activity and adrenergic central and/or dopaminergic stimulating action; 2) L-Dopa + chl. amantadine; 3) L-dopa + placebo. The patients were previously under exclusive use of L-dopa. The assay verifies: a) if there is any benefit with these associations and in what proportions; b) incidence and intensity of side effects; c) comparative study. The assay also intends to evaluate the effect of the G 31.406 on the depression which usually occur in Parkinsonians.

Amantadine↗